[ad_1]
MetLife Investment Management LLC reduced its stake in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 1.9% in the 1st quarter, HoldingsChannel.com reports. The firm owned 87,673 shares of the company’s stock after selling 1,684 shares during the quarter. MetLife Investment Management LLC’s holdings in Moderna were worth $2,486,000 as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. S Bank Fund Management Ltd acquired a new stake in shares of Moderna during the 1st quarter valued at $25,000. SVB Wealth LLC purchased a new stake in shares of Moderna during the first quarter worth $28,000. Costello Asset Management INC acquired a new stake in Moderna during the first quarter valued at $30,000. Vega Investment Solutions purchased a new position in Moderna in the fourth quarter valued at about $45,000. Finally, Sentry Investment Management LLC acquired a new position in Moderna in the 1st quarter worth about $31,000. Institutional investors and hedge funds own 75.33% of the company’s stock.
Analyst Ratings Changes
MRNA has been the subject of several research reports. Evercore ISI set a $32.00 price target on Moderna in a report on Friday, August 1st. William Blair reiterated a “market perform” rating on shares of Moderna in a research note on Monday, June 2nd. Wells Fargo & Company reissued an “equal weight” rating on shares of Moderna in a research report on Sunday, July 13th. Morgan Stanley restated an “equal weight” rating and set a $32.00 price target on shares of Moderna in a report on Friday, August 1st. Finally, JPMorgan Chase & Co. set a $26.00 price objective on shares of Moderna in a research note on Friday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, sixteen have given a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat.com, Moderna currently has a consensus rating of “Hold” and an average price target of $42.88.
Check Out Our Latest Research Report on Moderna
Moderna Stock Down 1.6%
Shares of MRNA stock opened at $24.09 on Tuesday. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $79.96. The company has a market cap of $9.37 billion, a PE ratio of -3.20 and a beta of 1.93. The business’s 50 day moving average is $29.05 and its two-hundred day moving average is $28.75.
Moderna (NASDAQ:MRNA – Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The business had revenue of $142.00 million during the quarter, compared to analysts’ expectations of $116.26 million. During the same period in the previous year, the company earned ($3.33) earnings per share. Moderna’s revenue for the quarter was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Moderna, Inc. will post -9.61 EPS for the current fiscal year.
About Moderna
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Further Reading
Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).
Receive News & Ratings for Moderna Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Moderna and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
Source link